Evidence map›Paper›PMID 40504425›Full record

Trial reportJapanese journal of ophthalmology2025

Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.

Yasuo Yanagi, Ryusaburo Mori, Kelvin Yi Chong Teo, Kyu-Hyung Park, Nor Fariza Ngah, Shih-Jen Chen, Paisan Ruamviboonsuk, Nagako Kondo, Won Ki Lee, Rajesh Rajagopalan and 9 more

Registry-linked trialAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01846273 (A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01846273 phase4completednot on this map

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

TypeinterventionalSponsorNovartis PharmaceuticalsRan2013 to 2017Enrolled321ConditionsAge-related Macular Degeneration, Polypoidal Choroidal VasculopathyArmsRanibizumab, Verteporfin PDT, Sham PDT
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yasuo YanagiRetina Research Group, Singapore Eye Research Institute, Singapore Eye-ACP, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. yasuo.yanagi.tokyo@gmail.com.ORCID http://orcid.org/0000-0002-0362-7285
Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Kelvin Yi Chong TeoRetina Research Group, Singapore Eye Research Institute, Singapore Eye-ACP, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Kyu-Hyung ParkDepartment of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Nor Fariza NgahHospital Selayang, Batu caves, Selangor, Malaysia.
Shih-Jen ChenDepartment of Ophthalmology, Taipei Veterans General Hospital, School of Medicine, National Yang Ming Chiao Yung University, 201 Shih-Pai Road, Taipei, 112, Taiwan.
Paisan RuamviboonsukDepartment of Ophthalmology, College of Medicine, Rangsit University, Rajavithi Hospital, Bangkok, Thailand.
Nagako KondoMiyake Eye Hospital Ophthalmology, Ozone, Kita-ku, Nagoya city, Japan.
Won Ki LeeNune Eye Hospital, Seoul, South Korea.
Rajesh RajagopalanTan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore, Singapore.
Ryo ObataThe University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Ian Y H WongHong Kong Sanatorium and Hospital, Happy Valley, Hong Kong.
Caroline CheeNational University Hospital, Singapore, Singapore.
Hiroko TerasakiNagoya University Hospital, Nagoya-city, Aichi, Japan.
Tetsuju SekiryuFukushima Medical University hospital, Fukushima-city, Fukushima, Japan.
Shih-Chou ChenKaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Timothy Y Y LaiDepartment of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong.
Gemmy CheungRetina Research Group, Singapore Eye Research Institute, Singapore Eye-ACP, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Shigeru HondaDepartment of Ophthalmology and Visual Sciences, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Funding

National Medical Research Council Singapore Open Fund Large Collaborative Grant NMRC/LCG/004/2018
6 · The paper itself

Abstract

purposeTo evaluate long-term outcomes for polypoidal choroidal vasculopathy (PCV) in Japanese patients in the EVEREST II study. STUDY

designA multicenter, cross-sectional study of the long-term outcomes of a cohort of patients originally treated with ranibizumab alone (monotherapy group) or in combination with photodynamic therapy PDT (combination group) in the EVEREST II study (ClinicalTrials.gov identifier, NCT01846273).

methodsNinety participants from the six-year EVEREST II follow-up: 20 Japanese and 70 non-Japanese were included. Long-term changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) were reported in the Japanese compared to non-Japanese participants. Number of injections, types of anti-vascular endothelial growth factor (VEGF) agents used, and cases with equal visits and injections, indicating fixed dosing or treat-and-extend (TAE) administration were investigated. Outcomes were also compared between those who had verteporfin PDT during the six-year period (n=14) and those who did not (n=6).

resultsThe Japanese and non-Japanese participants had similar baseline characteristics. The mean age for Japanese participants was 76±4.47 years, with 25% being women. BCVA improved from baseline to year 2 in both groups (P < 0.05). At six years, BCVA was maintained in the Japanese (67.2 ETDRS letters) but decreased in the non-Japanese participants (from 68.8 to 53.5 letters). The Japanese participants received more injections than the non-Japanese (12.5 vs. 7.57, P=0.017). Aflibercept was the most frequently used anti-VEGF agent, and the number of fixed dosing or TAE administration was higher in the Japanese participants. No significant differences were found in functional and anatomical outcomes between those who received PDT and those who did not (all P > 0.05). However, non-PDT participants had numerically worse BCVA at the final visit.

conclusionsThis study highlights positive long-term outcomes for Japanese PCV patients and underscores the need for further research to validate these findings in broader patient populations.

Indexed as

ChoroidChoroid DiseasesPhotochemotherapyPolypsRanibizumabVisual AcuityAgedAged, 80 and overAngiogenesis InhibitorsCross-Sectional StudiesEast Asian PeopleFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansAngiogenesis InhibitorsPhotosensitizing AgentsRanibizumabVascular Endothelial Growth Factor AVerteporfinAge-related macular degenerationPolypoidal choroidal vasculopathy

Identifiers

PMID40504425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.